Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49,625,327
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
4,027,160
-
Shares change
-
-1,230,692
-
Total reported value, excl. options
-
$5,919,504
-
Value change
-
-$1,196,574
-
Number of buys
-
9
-
Number of sells
-
7
-
Price
-
$1.47
Institutional Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q4 2023
23 filings reported holding CADL - Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share as of 31 Dec 2023.
Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) had 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 4,027,160 shares of stock of the company.
Largest 10 holders included Northpond Ventures, LLC, Sands Capital Ventures, LLC, VANGUARD GROUP INC, FMR LLC, GEODE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, Baystate Wealth Management LLC, BlackRock Inc., OneDigital Investment Advisors LLC, and STATE STREET CORP.
This table shows the top 21 institutional shareholders of the security as of 31 Dec 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.